echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Chi-Med began submitting Surufatinib's application to the FDA for the treatment of advanced neuroendocrine tumors

    Chi-Med began submitting Surufatinib's application to the FDA for the treatment of advanced neuroendocrine tumors

    • Last Update: 2021-01-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Neuroendocrine tumors are tumors that originate from neuroendocrine cells.
    neuroendocrine cells are a large class of cells in the body that have neuroendocrine esologies and can produce a variety of hormones.
    China Medical Technology Co., Ltd. (Chi-Med) today announced that it has begun filing with the U.S. Food and Drug Administration (FDA) a new drug application (NDA) for Surufatinib's treatment of pancreatic and non-pancreatic neuroendocrine tumors.
    Chi-Med plans to complete the NDA submission in the first half of 2021, which will be the company's first NDA in the United States.
    NDA is based on two positive Phase III studies in China and from patients with non-pancreatic and pancreatic neuroendocrine tumors in the United States.
    based on the scientific recommendations of the Human Medicines Commission (CHMP), the package will also be used to submit a sales authorization application (MAA) to the European Medicines Agency (EMA).
    Surufatinib has shown significant clinical benefits in patients with advanced oncology, and the NDA application to the FDA marks an important step toward the goal of commercializing surufatinib and other new therapies," said Dr. Marek Kania, chief medical officer of chi-Med.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.